RHEUMATOLOGY GRAND ROUNDS

*Presented by*

Yale School of Medicine’s, Department of Internal Medicine,

Section of Rheumatology

**“A Case-based Review of Therapeutic Options in RA-ILD:  Biologics as Therapy Choices”**

 **Gordon Hutchinson, MD, FACR**

Associate Professor of Clinical Medicine

**Date: Wednesday, December 11, 2019**

**Location: 300 Cedar St., TAC Building Room N-203**

**Time: 8:00-9:00 am**

**Course Director/Host: Fotios Koumpouras, MD**

***There is no corporate support for this activity***

This course will fulfill the licensure requirement set forth by the State of Connecticut

**ACCREDITATION**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**TARGET AUDIENCE**

Department faculty, attending physicians, subspecialty fellows, community physicians, resident house staff, physician assistants and medical students.

**NEEDS ASSESSMENT**

Clinically significant interstitial lung disease (ILD) develops as a complication of rheumatoid arthritis (RA) in around 10 percent of patients. The clinical course of RA-ILD can be variable, from asymptotic disease to life-threatening and progressive pulmonary fibrosis. Improved recognition and understanding of this disease might lead to better patient outcomes and more effective treatment. This presentation will review the clinical spectrum of RA-ILD including the major subtypes of disease and their pathobiological characteristics. Practitioners will gain an improved ability to recognize and treat patients with RA-ILD

**LEARNING OBJECTIVES**

At the conclusion of this activity, participants will be able to:

1. Review of ILD as a complication of RA
2. Review known clinical types and current pathobiology
3. Review problems associated with therapeutic options & recommendations

**DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY DISCLOSURES**

*Speaker:* Gordon Hutchinson, MD – NONE

*Course Director:* Fotios Koumpouras, MD- Celgene (honorarium), Aurora (research grant), EMD, ULB, GSK (research grant)

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.